DSpace logo

Please use this identifier to cite or link to this item: http://dspace.bits-pilani.ac.in:8080/jspui/handle/123456789/13863
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSundriyal, Sandeep-
dc.date.accessioned2024-01-17T09:05:20Z-
dc.date.available2024-01-17T09:05:20Z-
dc.date.issued2020-01-
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0968089619311939-
dc.identifier.urihttp://dspace.bits-pilani.ac.in:8080/jspui/xmlui/handle/123456789/13863-
dc.description.abstractFalcipains (FPs), cysteine proteases in the malarial parasite, are emerging as the promising antimalarial drug targets. In order to identify novel FP inhibitors, we generated a pharmacophore derived from the reported co-crystal structures of inhibitors of Plasmodium falciparum Falcipain-3 to screen the ZINC library. Further, the filters were applied for dock score, drug-like characters, and clustering of similar structures. Sixteen molecules were purchased and subject to in vitro enzyme (FP-2 and FP-3) inhibition assays. Two compounds showed in vitro inhibition of FP-2 and FP-3 at low µM concentration. The selectivity of the inhibitors can be explained based on the predicted interactions of the molecule in the active site. Further, the inhibitors were evaluated in a functional assay and were found to induce morphological changes in line with their mode of action arresting Plasmodium development. Compound 15 was most potent inhibitor identified in this study.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.subjectPharmacyen_US
dc.subjectMalariaen_US
dc.subjectCysteine proteasesen_US
dc.subjectDockingen_US
dc.subjectPharmacophoreen_US
dc.subjectFalcipain-2en_US
dc.titleIdentification of antimalarial leads with dual falcipain-2 and falcipain-3 inhibitory activityen_US
dc.typeArticleen_US
Appears in Collections:Department of Pharmacy

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.